Emerging biotech leader AKESF develops Ivonescimab & Cadonilimab; while offering growth potential with US partnerships, ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

CytomX Therapeutics, Inc.’s CTMX share price has surged by 6.39%, which has investors questioning if this is right time to ...

In the global arena of biomedicine, Guangzhou's innovative drug companies are rewriting the rules with "hard‑core technology.

ProBio's proprietary platform utilizes an optimized single-domain antibody (sdAb) targeting CD3, overcoming these challenges by enablingthe development of highly adaptable bispecific and multi ...

SPX-303, a first-in-class bispecific antibody targeting LILRB2 and PD-L1 ... our mission of empowering investor success. We provide a platform for our authors to report on investments fairly ...

ABL Bio enters Grabody-B brain delivery platform license pact with GSK to develop novel medicines for neurodegenerative diseases: Seongnam, South Korea Tuesday, April 8, 2025, 17: ...

Earendil Labs and Sanofi today announced that they have entered into a license agreement for two potential first-in-class ...